These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 18793655

  • 1. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
    Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D.
    Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
    [Abstract] [Full Text] [Related]

  • 2. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
    Radek RJ, Robb HM, Stevens KE, Gopalakrishnan M, Bitner RS.
    J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
    [Abstract] [Full Text] [Related]

  • 3. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist.
    Feuerbach D, Nozulak J, Lingenhoehl K, McAllister K, Hoyer D.
    Neurosci Lett; 2007 Apr 06; 416(1):61-5. PubMed ID: 17314009
    [Abstract] [Full Text] [Related]

  • 4. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice.
    Schreiber R, Dalmus M, De Vry J.
    Psychopharmacology (Berl); 2002 Jan 06; 159(3):248-57. PubMed ID: 11862357
    [Abstract] [Full Text] [Related]

  • 5. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):875-86. PubMed ID: 20504913
    [Abstract] [Full Text] [Related]

  • 6. Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors.
    Arias HR, De Rosa MJ, Bergé I, Feuerbach D, Bouzat C.
    Biochemistry; 2013 Nov 26; 52(47):8480-8. PubMed ID: 24164482
    [Abstract] [Full Text] [Related]

  • 7. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
    Pieschl RL, Miller R, Jones KM, Post-Munson DJ, Chen P, Newberry K, Benitex Y, Molski T, Morgan D, McDonald IM, Macor JE, Olson RE, Asaka Y, Digavalli S, Easton A, Herrington J, Westphal RS, Lodge NJ, Zaczek R, Bristow LJ, Li YW.
    Eur J Pharmacol; 2017 Jul 15; 807():1-11. PubMed ID: 28438647
    [Abstract] [Full Text] [Related]

  • 8. (R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.
    Tatsumi R, Fujio M, Takanashi S, Numata A, Katayama J, Satoh H, Shiigi Y, Maeda J, Kuriyama M, Horikawa T, Murozono T, Hashimoto K, Tanaka H.
    J Med Chem; 2006 Jul 13; 49(14):4374-83. PubMed ID: 16821797
    [Abstract] [Full Text] [Related]

  • 9. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism.
    Simosky JK, Stevens KE, Adler LE, Freedman R.
    Psychopharmacology (Berl); 2003 Feb 13; 165(4):386-96. PubMed ID: 12459928
    [Abstract] [Full Text] [Related]

  • 10. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF, Freedman R.
    Int Rev Neurobiol; 2007 Feb 13; 78():225-46. PubMed ID: 17349863
    [Abstract] [Full Text] [Related]

  • 11. Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor.
    Arias HR, Gu RX, Feuerbach D, Wei DQ.
    Biochemistry; 2010 May 18; 49(19):4169-80. PubMed ID: 20377277
    [Abstract] [Full Text] [Related]

  • 12. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
    Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC.
    J Pharmacol Exp Ther; 2009 May 18; 329(2):459-68. PubMed ID: 19223665
    [Abstract] [Full Text] [Related]

  • 13. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
    Mastropaolo J, Rosse RB, Deutsch SI.
    Behav Brain Res; 2004 Aug 31; 153(2):419-22. PubMed ID: 15265637
    [Abstract] [Full Text] [Related]

  • 14. Effects of nicotine vary across two auditory evoked potentials in the mouse.
    Metzger KL, Maxwell CR, Liang Y, Siegel SJ.
    Biol Psychiatry; 2007 Jan 01; 61(1):23-30. PubMed ID: 16497274
    [Abstract] [Full Text] [Related]

  • 15. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT.
    J Pharmacol Exp Ther; 1994 Jul 01; 270(1):319-28. PubMed ID: 7913497
    [Abstract] [Full Text] [Related]

  • 16. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
    Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G.
    Neuropharmacology; 2012 Feb 01; 62(2):1099-110. PubMed ID: 22085888
    [Abstract] [Full Text] [Related]

  • 17. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
    Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B.
    Neuropsychopharmacology; 2007 Jan 01; 32(1):17-34. PubMed ID: 16936709
    [Abstract] [Full Text] [Related]

  • 18. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.
    Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C, Jonak G, Gurley D, Gordon JC, Christian EP, Doherty JJ, Hudzik T, Johnson E, Mrzljak L, Piser T, Smagin GN, Wang Y, Widzowski D, Smith JS.
    Biochem Pharmacol; 2009 Oct 01; 78(7):880-8. PubMed ID: 19615981
    [Abstract] [Full Text] [Related]

  • 19. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
    Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G.
    J Pharmacol Exp Ther; 2007 May 01; 321(2):716-25. PubMed ID: 17308038
    [Abstract] [Full Text] [Related]

  • 20. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.
    Arch Gen Psychiatry; 2006 Jun 01; 63(6):630-8. PubMed ID: 16754836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.